| Background: Ovarian cancer (OC) is one of the worrisome gynecological cancers worldwide. Given its consid-
erable mortality rate, it is necessary to investigate its oncogenesis.
Methods: In this study, we used systems biology approaches to describe the key gene modules, hub genes, and
regulatory drugs associated with serous OC as the novel biomarkers using weighted gene co-expression network
analysis (WGCNA).
Findings: Our findings have demonstrated that the blue module genes (r = 0.8, p-value = 1e-16) are involved in
OC progression. Based on gene enrichment analysis, the genes in this module are frequently involved in bio-
logical processes such as the Cyclic adenosine monophosphate (cAMP) signaling pathway and the cellular
response to transforming growth factor-beta stimulation. The co-expression network has been built using the
correlated module’s top hub genes, which are ADORA1, ANO9, CD24P4, CLDN3, CLDN7, ELF3, KLHL14, PRSS8,
RASAL1, RIPK4, SERINC2, and WNT7A. Finally, a drug-target network has been built to show the interaction of
the FDA-approved drugs with hub genes.
Conclusions: Our results have discovered that ADORA1, ANO9, SERINC2, and KLHL14 are hub genes associated
with serous OC. These genes can be considered as novel candidate target genes for treating OC. |